Resumen de acción BIOV.F Swedish Orphan Biovitrum AB (publ), empresa biotecnológica integrada, investiga, desarrolla, fabrica y vende productos farmacéuticos en las áreas terapéuticas de hematología, inmunología y cuidados especializados en Europa, Norteamérica, Oriente Medio, Asia y Australia. Saber más
Recompensas Análisis de riesgos Ver todos los controles de riesgos Captura tus ideas, enlaces y narrativas de la empresa
Competidores de Swedish Orphan Biovitrum AB (publ) Historial de precios y rendimiento
Resumen de las cotizaciones máximas, mínimas y variaciones del Swedish Orphan Biovitrum Precios históricos de las acciones Precio actual de la acción SEK 27.66 Máximo en las últimas 52 semanas SEK 32.25 Mínimo de 52 semanas SEK 22.87 Beta 0.24 Cambio en 1 mes -2.26% Variación en 3 meses -11.64% Cambio de 1 año 13.59% Variación en 3 años 38.33% Variación en 5 años 70.22% Variación desde la OPV 178.97%
Noticias y actualizaciones recientes
Swedish Orphan Biovitrum AB (Publ) Elects David Meek as Member of the Board of Directors and Chair of the Board of Directors Dec 11
Swedish Orphan Biovitrum AB (Publ) Announces Annette Clancy Has Informed the Nomination Committee That Will Not Be Available for Re-Election as Chair Nov 05
Sobi and Apellis Pharmaceuticals, Inc. Announces Detailed Data from the Phase 3 Valiant Study Oct 28 Swedish Orphan Biovitrum AB (publ) to Report Fiscal Year 2024 Results on Mar 31, 2025 Swedish Orphan Biovitrum AB (publ) to Report Q2, 2025 Results on Jul 16, 2025
Sobi and Apellis Announce Positive Topline Results from Phase 3 Valiant Study of Pegcetacoplan in C3G and Primary IC-MPGN Aug 08 Ver más actualizaciones
Swedish Orphan Biovitrum AB (Publ) Elects David Meek as Member of the Board of Directors and Chair of the Board of Directors Dec 11
Swedish Orphan Biovitrum AB (Publ) Announces Annette Clancy Has Informed the Nomination Committee That Will Not Be Available for Re-Election as Chair Nov 05
Sobi and Apellis Pharmaceuticals, Inc. Announces Detailed Data from the Phase 3 Valiant Study Oct 28 Swedish Orphan Biovitrum AB (publ) to Report Fiscal Year 2024 Results on Mar 31, 2025 Swedish Orphan Biovitrum AB (publ) to Report Q2, 2025 Results on Jul 16, 2025
Sobi and Apellis Announce Positive Topline Results from Phase 3 Valiant Study of Pegcetacoplan in C3G and Primary IC-MPGN Aug 08
Sobi Announces the Publication of Full Results from the Phase 3 XTEND- Kids Study in Thenew England Journal of Medicine Confirming the Safety and Efficacy Profile of Altuvoct Jul 19
Swedish Orphan Biovitrum AB (publ) Updates Earnings Guidance for the Year 2024 Jul 17
Swedish Orphan Biovitrum AB (publ) Updates Earnings Guidance for the Year 2024 Jul 16
Sobi Initiates Rolling Biologics License Application to FDA for SEL-212 for the Potential Treatment of Chronic Refractory Gout Jul 02
European Commission Grants Sobi® Marketing Authorisation for Altuvoct™ for Treatment of Haemophilia A Jun 20
Swedish Orphan Biovitrum AB (publ) Elects Zlatko Rihter as New Board Member May 15
Swedish Orphan Biovitrum AB (Publ) Provides Earnings Guidance for 2024 Apr 28 Swedish Orphan Biovitrum AB (publ) to Report Q4, 2024 Results on Feb 05, 2025
Swedish Orphan Biovitrum AB (publ) to Report Fiscal Year 2023 Final Results on Apr 02, 2024 Feb 29
Swedish Orphan Biovitrum AB (Publ) Provides Revenue Guidance for the Year 2024 Feb 08
Swedish Orphan Biovitrum AB (Publ) Announces Resignation of Bo Jesper Hansen as Chairman of the Board and Board Member Jan 05
Swedish Orphan Biovitrum AB (publ), Annual General Meeting, May 14, 2024 Oct 31
Sobi and Apellis Pharmaceuticals, Inc. Announce Positive Results from Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G Oct 18
Sobi Appoints Lydia Abad-Franch as Head of R&D and Chief Medical Officer Oct 05 Sanofi S.A. and Sobi Announce Once-Weekly ALTUVIIIO Approved in Japan as A New Class of Factor VIII Therapy for Hemophilia A Sep 25
Swedish Orphan Biovitrum AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 6.023593 billion. Sep 21 Swedish Orphan Biovitrum AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 6.023593 billion. Sep 20
Swedish Orphan Biovitrum AB (publ) to Report Q3, 2024 Results on Oct 24, 2024
Swedish Orphan Biovitrum AB (publ) (OM:SOBI) completed the acquisition of CTI BioPharma Corp. (NasdaqCM:CTIC) from a group of shareholders. Jun 27
European Medicines Agency Validates Sobi's Marketing Authorisation Application for Efanesoctocog Alfa for Treatment of Haemophilia A May 19
Swedish Orphan Biovitrum AB (publ) (OM:SOBI) entered into a definitive agreement and plan of merger to acquire CTI BioPharma Corp. (NasdaqCM:CTIC) from a group of shareholders for $1.2 billion. May 11
Swedish Orphan Biovitrum AB (Publ) Approves Election of Christophe Bourdon and Anders Ullman as Members of the Board May 10
Swedish Orphan Biovitrum AB (Publ) Provides Earnings Guidance for 2023 Feb 08
Swedish Orphan Biovitrum AB (Publ) Announces Executive Changes Feb 03
ADC Therapeutics SA and Swedish Orphan Biovitrum AB Announce the European Commission Approval of Zynlonta® (Loncastuximab Tesirine) Dec 21
Sobi North America, the North American Affiliate of Swedish Orphan Biovitrum AB Announces That U.S. Food and Drug Administration Issues Emergency Use Authorization for Kineret® (Anakinra) for the Treatment of Covid-19-Related Pneumonia Nov 11
Swedish Orphan Biovitrum AB (Publ)'s Chairman of the Board Håkan Björklund Will Not Be Available for Re-Election At the Annual General Meeting 2023 Nov 01 Swedish Orphan Biovitrum AB (publ) to Report Q3, 2023 Results on Oct 26, 2023
ADC Therapeutics and Sobi Announce ZYNLONTA® (loncastuximab tesirine) Receives Positive CHMP Opinion in Europe for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma Sep 17
Sanofi and Sobi Announce US Food and Drug Administration Accept Priority Review the Biologics License Application for efanesoctocog alfa Aug 30
Swedish Orphan Biovitrum AB (publ) Provides Revenue Guidance for the Year 2022 Jul 20
Apellis Pharmaceuticals, Inc. and Sobi(R) Report New Data Reinforcing the Robust Efficacy and Safety Profile of EMPAVELI (pegcetacoplan) for PNH at EHA 2022 Congress Jun 10
Apellis Pharmaceuticals, Inc. and Sobi Announces First Patient Dosed in Phase 3 VALIANT Study of Pegcetacoplan for IC-MPGN and C3G, Rare Kidney Diseases with High Unmet Medical Need Jun 08
FDA Grants efanesoctocog alfa Breakthrough Therapy Designation for Hemophilia A by Sanofi and Sobi Jun 01
Swedish Orphan Biovitrum AB (publ) Elects Bo Jesper Hansen as New Board Member May 12
Sanofi and Swedish Orphan Biovitrum AB Announce Positive Topline Results from the Pivotal XTEND-1 Phase 3 Study Mar 10
Gamifant (Emapalumab) Recommends for Approval in China for Treatment of Primary Haemophagocytic Lymphohistiocytosis (HLH) Feb 26
Swedish Orphan Biovitrum AB (publ), Annual General Meeting, May 10, 2022 Feb 01
Kineret® (Anakinra) Receives Positive Opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency for Treatment of Patients with Covid-19 Pneumonia Dec 18 Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB (Publ) Announce EU Approval of Aspaveli® (Pegcetacoplan) for Treatment of PNH
Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB (publ) Report Empaveli™ Demonstrated Sustained Normalization of Clinical Measures in a Broad PNH Patient Population Dec 15
Advent International Corporation and GIC Special Investments Pte. Ltd. cancelled the acquisition of Swedish Orphan Biovitrum AB (publ) (OM:SOBI) from Investor AB (publ) (OM:INVE A), AP Fonden 4 and others. Dec 05
Swedish Orphan Biovitrum AB (publ) Publishes Positive Phase 3 Anakinra Study Results in Patients with COVID-19 Pneumonia Sep 08
Nature Medicine Publishes Phase 3 Anakinra Study Results in Patients with Covid-19 Pneumonia Sep 04
Orphan Biovitrum Jumps After Bloomberg Report of Potential Takeover Aug 27
Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB (Publ) Report Positive Top-Line Results from the Phase 3 Prince Study of EMPAVELI™ (pegcetacoplan) in Treatment-naïve Patients with PNH May 26
Swedish Orphan Biovitrum AB (publ) Announces Early Use of Anakinra Reduces Risk of Mortality for Patients with Covid-19 Pneumonia, Reduces ICU Admission and Increases Likelihood of Full Recovery May 21
Swedish Orphan Biovitrum AB (Publ) and Hellenic Institute for the Study Announce Positive Top Line Results from the Investigator-Sponsored Save-More Study May 05
Swedish Orphan Biovitrum AB (Publ) Provides Revenue Guidance for the Full Year 2021 May 04
The NEJM Publishes Phase 3 PEGASUS Study Results Comparing Pegcetacoplan to Eculizumab for PNH Mar 19
Swedish Orphan Biovitrum AB (publ) Announces First Patient Dosed with Avatrombopag Mar 13
Swedish Orphan Biovitrum AB (publ) Announces Approval of Kineret® (anakinra) in Russia for the Treatment of CAPS Feb 18
Swedish Orphan Biovitrum AB (publ) Announces Doptelet (avatrombopag) Approved in the EU for Treatment of ITP Jan 22
Swedish Orphan Biovitrum AB (Publ) Appoints Duane Barnes as the New Head of Sobi in North America Dec 23 Swedish Orphan Biovitrum's Doptelet® (Avatrombopag) Receives Positive Opinion from CHMP for Treatment of ITP
Swedish Orphan Biovitrum AB and Apellis Pharmaceuticals Inc. Reports Positive Top-Line Results At 48 Weeks from the Phase 3 Pegasus Study of Pegcetacoplan in PNH Dec 11
Sobi and Apellis Announce First Patient Dosed in Potentially Registrational ALS Study of Pegcetacoplan Nov 20
Swedish Orphan Biovitrum AB (publ) Announces CHMP Adopts Negative Opinion for Emapalumab in Europe for the Treatment of Primary HLH Nov 14
Sobi launch Doptelet® (avatrombopag) in Europe Nov 05
Swedish Orphan Biovitrum AB (Publ) Announces Favorable Paediatric Data Results in Alprolix ® Product Information Update Oct 30
Apellis, Enters Strategic Collaboration with Sobi to Develop and Commercialize Pegcetacoplan in Hematologic Indications Outside the US Oct 29
Sobi™ Presents Results from the Sensitivity Analysis from the Pivotal Phase 2/3 Study Oct 18
Swedish Orphan Biovitrum AB (Publ) Announces Phase 3 Data of Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia Oct 11
Selecta Biosciences and Sobi Announce Topline Data of SEL-212 from the Phase 2 COMPARE Trial Supporting the Potential for Important Clinical Improvement in Patients with Chronic Refractory Gout Oct 02 Swedish Orphan Biovitrum AB (Publ) and Selecta Biosciences, Inc. Announce Topline Data of SEL-212 from the Phase 2 Compare Study
Swedish Orphan Biovitrum AB (Publ) Announces the Commencement of the Phase 3 Clinical programme of SEL-212 for Chronic Refractory Gout Sep 24
Swedish Orphan Biovitrum AB (publ) Announces Orfadin® (nitisinone) Receives Positive Opinion from CHMP for Treatment of AKU Sep 19 Rentabilidad de los accionistas BIOV.F US Biotechs Mercado US 7D -3.4% -3.3% -2.2% 1Y 13.6% -1.9% 23.9%
Ver rendimientos de los accionistas
Rentabilidad vs. Industria: BIOV.F superó a la industria US Biotechs, que obtuvo un rendimiento del -1.9% el año pasado.
Rentabilidad vs. Mercado: BIOV.F obtuvo unos resultados inferiores a los del mercado US, que fueron del 23.9% el año pasado.
Volatilidad de los precios Is BIOV.F's price volatile compared to industry and market? BIOV.F volatility BIOV.F Average Weekly Movement n/a Biotechs Industry Average Movement 10.7% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.0% 10% least volatile stocks in US Market 3.1%
Precio estable de las acciones: El precio de las acciones de BIOV.F ha sido volátil en los últimos 3 meses.
Volatilidad a lo largo del tiempo: Datos insuficientes para determinar el cambio de volatilidad de BIOV.F en el último año.
Acerca de la empresa Fundada Empleados CEO Página web 1939 1,814 Guido Oelkers www.sobi.com
Swedish Orphan Biovitrum AB (publ), empresa biotecnológica integrada, investiga, desarrolla, fabrica y vende productos farmacéuticos en las áreas terapéuticas de hematología, inmunología y atención especializada en Europa, Norteamérica, Oriente Medio, Asia y Australia. Ofrece Alprolix para la hemofilia B; Aspaveli®/Empaveli para el tratamiento de pacientes adultos con hemoglobinuria paroxística nocturna; Doptelet para el tratamiento de la trombocitopenia; Elocta para la hemofilia A; Gamifant para la linfohistiocitosis hemofagocítica (HLH); VONJO para el tratamiento de adultos con mielofibrosis primaria o secundaria (post-policitemia vera o post-trombocitemia esencial) de riesgo intermedio o alto; Zynlonta, una enfermedad maligna agresiva; Kineret para el síndrome periódico asociado a la criopirina, la artritis reumatoide y la enfermedad de Still; Orfadin para tratar la tirosinemia hereditaria de tipo 1; y Synagis para infecciones graves de las vías respiratorias bajas. La empresa también suministra otros productos, como Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi y Waylivra.
Mostrar más Resumen de fundamentos de Swedish Orphan Biovitrum AB (publ) ¿Cómo se comparan los beneficios e ingresos de Swedish Orphan Biovitrum con su capitalización de mercado? Estadísticas fundamentales de BIOV.F Capitalización bursátil US$9.66b Beneficios(TTM ) US$318.12m Ingresos (TTM ) US$2.30b
30.4x Ratio precio-beneficio (PE)
4.2x Ratio precio-ventas (PS) Beneficios e Ingresos Estadísticas clave de rentabilidad del último informe de resultados (TTM) Cuenta de resultados (TTM ) de BIOV.F Ingresos SEK 25.44b Coste de los ingresos SEK 5.44b Beneficio bruto SEK 19.99b Otros gastos SEK 16.48b Beneficios SEK 3.51b
Últimos beneficios comunicados
Sep 30, 2024
Próxima fecha de beneficios
Feb 05, 2025
Beneficios por acción (BPA) 10.23 Margen bruto 78.60% Margen de beneficio neto 13.82% Ratio deuda/patrimonio 47.1%
¿Cómo se ha desempeñado BIOV.F a largo plazo?
Ver rendimiento histórico y comparativa
Análisis de la empresa y estado de los datos financieros Datos Última actualización (huso horario UTC) Análisis de la empresa 2024/12/23 18:15 Precio de las acciones al final del día 2024/12/23 00:00 Beneficios 2024/09/30 Ingresos anuales 2023/12/31
Fuentes de datos Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC . Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
Paquete Datos Marco temporal Ejemplo Fuente EE.UU. * Finanzas de la empresa 10 años Cuenta de resultados Estado de tesorería Balance Estimaciones del consenso de analistas +3 años Previsiones financieras Objetivos de precios de los analistas Precios de mercado 30 años Precios de las acciones Dividendos, escisiones y acciones Propiedad 10 años Accionistas principales Información privilegiada Gestión 10 años Equipo directivo Consejo de Administración Principales avances 10 años
* ejemplo para los valores estadounidenses, para los no estadounidenses se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Obtenga más información aquí .
Modelo de análisis y copo de nieve Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github , también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube .
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en .
Fuentes analistas Swedish Orphan Biovitrum AB (publ) está cubierta por 29 analistas. 11 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
Analista Institución Alexander Lindström ABG Sundal Collier Rosie Turner Barclays Brian Balchin Barclays
Mostrar 26 más analistas 
